Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Premenstrual dysphoric disorder is a menstrually related disorder that intermittently causes disabling emotional, behavioral, and physical symptoms. The goal of the current study was to evaluate the efficacy and tolerability of sertraline for premenstrual dysphoric disorder when treatment was limited to the luteal phase. METHODS: Two hundred eighty-one women who met Diagnostic and Statistical Manual of Mental Disorders (4th edition) criteria for premenstrual dysphoric disorder and who completed two prospective screening cycles and one single-blind placebo cycle were randomized to three cycles of double-blind, luteal phase treatment with either a placebo or sertraline in a flexible daily dose of 50-100 mg. Outcome measures included the Daily Record of Severity of Problems and the Clinical Global Impression Severity and Improvement scales. RESULTS: Luteal phase treatment with sertraline was significantly superior to the placebo, as demonstrated by end- point analysis of Clinical Global Impression Improvement scale scores (sertraline, 2.3 +/- 1.1, versus placebo, 2.7 +/- 1.1; P <.001), and cycle 3 Daily Record of Severity of Problems change scores (sertraline, 27.6 +/- 26.8, versus placebo, 17.6 +/- 23.3; P <.002). A significant difference was also noted in responder rates in favor of sertraline (50%) versus placebo (26%, P <.001) by cycle 1 (with responder defined as a Clinical Global Impression Improvement scale score of 1 or 2). Quality of life and functioning outcomes were also significantly improved. Intermittent luteal administration of sertraline was well tolerated, with only approximately 8% of patients on sertraline and less than 1% on placebo discontinuing because of adverse events. CONCLUSION: Sertraline was significantly more effective than a placebo and was well tolerated as a treatment for premenstrual dysphoric disorder when administered intermittently during the luteal phase of the menstrual cycle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessment of social adjustment by patient self report.
Weissman, M. M. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770090101010 · Cited by 1,782 · cited 2×
“Functional impairment affecting interpersonal relationships and role function was also evaluated by means of the patient-rated 56-item Social Adjustment Scale.32 This scale evaluates the status of a patient’s relationships with his or her spouse, children, and other family members.”
MethodSchmidt, P. J., Nieman, L. K., Danaceau, M. A., Adams, L. F., & Rubinow, D. R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801223380401 · Cited by 765 · cited 2×
“The abnormal neurotransmitter function is probably modulated by menstrually related fluctuation in gonadal hormones, sensitivity to which might be amended in women with PMS.(11,14,15) Given the apparent link to serotonergic dysfunction, it is not surprising that agents blocking the serotonin transporter, including sel…”
BackgroundPrevalence, incidence and stability of premenstrual dysphoric disorder in the community
WITTCHEN, H.-U., BECKER, E., LIEB, R., & KRAUSE, P. (2002) · Psychological Medicine · doi:10.1017/s0033291701004925 · Cited by 554
Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: A systematic review
Dimmock, P. W., Wyatt, K. M., Jones, P. W., & O'Brien, P. S. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02754-9 · Cited by 368 · cited 4×
“Two main treatment approaches have demonstrated consistent efficacy: suppression of ovulation(14) and treatment with antidepressants, mainly selective serotonin reuptake inhibitors.(16) Several large, well-designed, placebo-controlled studies have been reported that demonstrate the efficacy of the selective serotonin…”
BackgroundMethodResultInfluential
Cited by
Quality-of-Life Impairment in Depressive and Anxiety Disorders
Rapaport, M. H., Clary, C., Fayyad, R., & Endicott, J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1171 · Cited by 914
The premenstrual symptoms screening tool (PSST) for clinicians
Steiner, M., Macdougall, M., & Brown, E. (2003) · Archives of Women's Mental Health · doi:10.1007/s00737-003-0018-4 · Cited by 641
“Prospective daily charting has been used primarily in PMS=PMDD randomized clinical trials (Sundblad et al., 1993; Steiner et al., 1995; Yonkers et al., 1997; Wikander et al., 1998; Freeman et al., 1999; Pearlstein et al., 2000; Dimmock et al., 2000; Halbreich et al., 2002; Cohen et al., 2002).”
MethodYonkers, K. A., O'Brien, P. S., & Eriksson, E. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60527-9 · Cited by 541
Selective serotonin reuptake inhibitors for premenstrual syndrome
Marjoribanks, J., Brown, J., O'Brien, P. M. S., & Wyatt, K. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001396.pub3 · Cited by 413
Premenstrual dysphoric disorder: Evidence for a new category for DSM-5
Epperson, C. N., Steiner, M., Hartlage, S. A., Eriksson, E., Schmidt, P. J., Jones, I., & Yonkers, K. A. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11081302 · Cited by 361
Self-citation
Metadata
- Authors
- Halbreich, U.
- Venue
- Obstetrics & Gynecology
- Published
- 2002-12
- Volume
- 100
- Issue
- 6
- Pages
- 1219-1229
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W1964089565
- Cited by
- 123
- References
- 4
- FWCI
- 10.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. https://app.cochat.ai/papers/10.1016/s0029-7844(02)02326-8
- The paper
- Halbreich, U. (2002). Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstetrics & Gynecology. https://doi.org/10.1016/s0029-7844(02)02326-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.